Financial Performance - The company's operating revenue for the first half of 2024 was ¥102,938,718.85, a decrease of 47.20% compared to ¥194,970,750.78 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was ¥17,056,132.14, down 68.55% from ¥54,226,331.53 in the previous year[13]. - The basic earnings per share decreased by 81.43% to ¥0.13 from ¥0.70 in the same period last year[13]. - Operating revenue declined by 47.20% year-on-year, indicating a challenging market environment[17]. - Net profit decreased by 69.70%, reflecting significant operational difficulties[17]. - The company reported a net profit margin decline due to increased operational costs and reduced revenue, impacting overall profitability[70]. - The company's net profit for the first half of 2024 was CNY 23,803,932.74, a decrease from CNY 50,874,977.87 in the same period of 2023, representing a decline of approximately 53.2%[72]. - The total profit for the first half of 2024 was CNY 26,438,105.69, down from CNY 58,213,120.22 in the same period of 2023, a decrease of around 54.5%[72]. Revenue and Sales - Total revenue for the company was 102,938,718.85 CNY, a decrease of 58.40% in domestic sales compared to the same period last year[36][38]. - The revenue from hybrid stepper motors decreased by 32.83% year-over-year, primarily due to market fluctuations in the industrial control sector[38]. - Linear actuators saw a revenue decline of 17.17% year-over-year, attributed to temporary market impacts in the medical device industry[38]. - The company reported a significant drop in revenue from voice coil motors, down 95.72% year-over-year, due to the previous year's surge in demand for medical ventilators[38]. - The revenue from domestic operations is $59,850,576.59, a significant decrease from $143,861,358.27 in the same period last year[153]. - The revenue from overseas operations is $43,088,142.26, compared to $51,109,392.51 in the same period last year, reflecting a decline of 15.7%[153]. Assets and Liabilities - Total assets increased by 0.54% to ¥719,791,479.74 compared to the previous year[14]. - Total liabilities rose significantly by 49.24% to ¥71,933,809.83, impacting the debt-to-asset ratio which increased to 9.99%[14]. - The company's total assets as of June 30, 2024, amounted to CNY 715,594,915.35, compared to CNY 706,119,499.16 at the end of 2023, reflecting a slight increase of approximately 1.7%[68]. - Total liabilities increased to CNY 67,207,183.58 in the first half of 2024 from CNY 43,141,755.45 in the same period of 2023, marking an increase of about 55.8%[69]. - The company's equity attributable to shareholders decreased to CNY 648,387,731.77 as of June 30, 2024, down from CNY 662,977,743.71 at the end of 2023, a decline of approximately 2.2%[69]. Research and Development - The company completed the R&D of a high-frequency breathing module for infant ventilators, significantly improving reliability and operational lifespan[24]. - The company has established a comprehensive R&D process focused on both independent and collaborative development to enhance product performance and expand its technology portfolio[21]. - Research and development expenses for the current period amount to $16,730,808.56, an increase of 13.9% from $14,678,998.14 in the same period last year[155]. - The company incurred research and development expenses of CNY 11,100,186.55 in the first half of 2024, slightly down from CNY 11,110,080.09 in the first half of 2023[72]. Market Strategy and Partnerships - The company maintains a "make-to-order" production model, allowing flexibility in production based on customer demand[20]. - The sales strategy includes direct sales and distribution, targeting both domestic and international markets, with a focus on regions such as South China and East China[20]. - The company entered into a strategic partnership with AIDIN Robotics to distribute advanced sensor products in China, enhancing its market presence[25]. - The company is focused on optimizing and innovating its core competencies in micro-motors for medical and industrial automation sectors, while also accelerating its entry into new fields within humanoid robotics[27]. Financial Management - The report was not audited by an accounting firm, and the management guarantees the accuracy and completeness of the financial data[3]. - The company has not faced any delisting risks as per the report[5]. - The company has established a proactive approach to manage inventory levels in response to potential declines in demand for ventilators and testing products[3]. - The company has set aside provisions for inventory depreciation due to prolonged inventory turnover times, indicating a cautious approach to market fluctuations[3]. - The company has recognized a need for talent development and innovation, establishing a dual-channel development mechanism and enhancing academic exchanges to foster employee R&D capabilities[3]. Shareholder Information - The total share capital increased from 96,044,078 shares to 134,461,709 shares due to a stock dividend distribution[56]. - The company’s major shareholders include Jiangsu Leili Electric Co., Ltd. with a 34.53% stake and Ding Quanjun with a 17.92% stake[57]. - The company plans to distribute a cash dividend of RMB 4 per share (including tax), totaling RMB 38,417,631.20, based on a total share capital of 96,044,078 shares[87]. Risk Management - The company is facing risks related to the potential loss of technical personnel, which could impact its innovation capabilities and competitive advantage[44]. - The company has faced risks related to raw material price fluctuations, particularly for motors, stator components, and lead screws, which are closely tied to copper and steel prices[3]. - The company has established risk management strategies to balance risk and return, focusing on minimizing negative impacts on performance[178]. - The company’s liquidity risk management includes a combination of short-term and long-term financing to maintain flexibility[180]. Compliance and Governance - The company adheres to the accounting standards and principles, ensuring that the financial statements accurately reflect its financial position and performance[89]. - The company has not engaged in any strategic investments or directed offerings during the reporting period[59]. - The board of directors consists of 7 members, while the supervisory board has 3 members[61].
鼎智科技(873593) - 2024 Q2 - 季度财报